11 research outputs found
Management of Multi Drug Resistance Tuberculosis in the Field: Tuberculosis Research Centre Experience
Setting: Multi-drug TB resistant (resistant to isoniazid and rifampicin) patients identified from a rural and urban area.
Objective: To study the feasibility of managing MDR TB patients under field conditions where DOTS programme has been
implemented
Methods: MDR TB Patients identified among patients treated under DOTS in the rural area and from cases referred by the
NGO when MDR TB was suspected form the study population. Culture and drug susceptibility testing were done at Tuberculosis
Research Centre (TRC). Treatment regimen was decided on individual basis. After a period of initial hospitalization, treatment
was continued in the respective peripheral health facility or with the NGO after identifying a DOT provider in the field.
Patients attended TRC at monthly intervals for clinical, sociological and bacteriological evaluations. Drugs for the month were
pre-packed and handed over to the respective center.
Results: A total of 66 MDR TB patients (46 from the rural and 20 from the NGO) started on treatment form the study
population and among them 20 (30%) were resistant to one or more second line drugs (Eto, Ofx, Km) including a case of
“XDR TB”. Less than half the patients stayed in the hospital for more than 10 days. The treatment was provided partially
under supervision. Providing injection was identified to be a major problem. Response to treatment could be correctly predicted
based on the 6-month smear results in 40 of 42 regular patients. Successful treatment outcome was observed only in 37% of
cases with a high default of 24%. Adverse reactions necessitating modification of treatment was required only for three
patients.
Implications Despite having reliable DST and drug logistics, the main challenge was to maintain patients on such prolonged
treatment by identifying a provider closer to the patient who can also give injection, have social skills and manage of minor
adverse reactions
Peri-operative red blood cell transfusion in neonates and infants: NEonate and Children audiT of Anaesthesia pRactice IN Europe: A prospective European multicentre observational study
BACKGROUND: Little is known about current clinical practice concerning peri-operative red blood cell transfusion in neonates and small infants. Guidelines suggest transfusions based on haemoglobin thresholds ranging from 8.5 to 12 g dl-1, distinguishing between children from birth to day 7 (week 1), from day 8 to day 14 (week 2) or from day 15 (≥week 3) onwards. OBJECTIVE: To observe peri-operative red blood cell transfusion practice according to guidelines in relation to patient outcome. DESIGN: A multicentre observational study. SETTING: The NEonate-Children sTudy of Anaesthesia pRactice IN Europe (NECTARINE) trial recruited patients up to 60 weeks' postmenstrual age undergoing anaesthesia for surgical or diagnostic procedures from 165 centres in 31 European countries between March 2016 and January 2017. PATIENTS: The data included 5609 patients undergoing 6542 procedures. Inclusion criteria was a peri-operative red blood cell transfusion. MAIN OUTCOME MEASURES: The primary endpoint was the haemoglobin level triggering a transfusion for neonates in week 1, week 2 and week 3. Secondary endpoints were transfusion volumes, 'delta haemoglobin' (preprocedure - transfusion-triggering) and 30-day and 90-day morbidity and mortality. RESULTS: Peri-operative red blood cell transfusions were recorded during 447 procedures (6.9%). The median haemoglobin levels triggering a transfusion were 9.6 [IQR 8.7 to 10.9] g dl-1 for neonates in week 1, 9.6 [7.7 to 10.4] g dl-1 in week 2 and 8.0 [7.3 to 9.0] g dl-1 in week 3. The median transfusion volume was 17.1 [11.1 to 26.4] ml kg-1 with a median delta haemoglobin of 1.8 [0.0 to 3.6] g dl-1. Thirty-day morbidity was 47.8% with an overall mortality of 11.3%. CONCLUSIONS: Results indicate lower transfusion-triggering haemoglobin thresholds in clinical practice than suggested by current guidelines. The high morbidity and mortality of this NECTARINE sub-cohort calls for investigative action and evidence-based guidelines addressing peri-operative red blood cell transfusions strategies. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02350348
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
___Key messages___
The Commission recommends five priority investments to achieve a tuberculosis-free world within a generation. These investments are designed to fulfil the mandate of the UN High Level Meeting on tuberculosis. In addition, they answer